Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xenetic Biosciences (XBIO) EBIT (2023 - 2025)

Xenetic Biosciences (XBIO) has disclosed EBIT for 6 consecutive years, with -$544734.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT fell 9.06% year-over-year to -$544734.0, compared with a TTM value of -$3.3 million through Sep 2025, up 24.08%, and an annual FY2024 reading of -$4.2 million, up 6.89% over the prior year.
  • EBIT was -$544734.0 for Q3 2025 at Xenetic Biosciences, up from -$724412.0 in the prior quarter.
  • Across five years, EBIT topped out at -$499473.0 in Q3 2024 and bottomed at -$1.3 million in Q2 2024.
  • Average EBIT over 3 years is -$993790.7, with a median of -$1.1 million recorded in 2024.
  • Peak annual rise in EBIT hit 56.44% in 2024, while the deepest fall reached 38.6% in 2024.
  • Year by year, EBIT stood at -$1.3 million in 2023, then increased by 12.47% to -$1.1 million in 2024, then soared by 50.44% to -$544734.0 in 2025.
  • Business Quant data shows EBIT for XBIO at -$544734.0 in Q3 2025, -$724412.0 in Q2 2025, and -$942409.0 in Q1 2025.